Lanean...
Risk versus benefit of chemoprevention among raloxifene and tamoxifen users with a family history of breast cancer
Tamoxifen and raloxifene have been approved for the primary prevention of breast cancer in high-risk women, but are associated with an increased risk of serious side effects. Few studies have characterized risk-benefit profiles for chemoprevention among women who initiate tamoxifen or raloxifene out...
Gorde:
| Argitaratua izan da: | Cancer Prev Res (Phila) |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6825574/ https://ncbi.nlm.nih.gov/pubmed/31431499 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1940-6207.CAPR-19-0021 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|